Adjuvant therapy with Huatan Sanjie Granules improves the prognosis of patients with primary liver cancer: a cohort study and the investigation of its mechanism of action based on network pharmacology.

Yuan, Juhua; Abdurahman, Abdusami; Cui, Ning; Hao, Tengteng; Zou, Jianhua; Liu, Liren; Wu, Yu

Yuan, Juhua; Abdurahman, Abdusami; Cui, Ning; Hao, Tengteng; Zou, Jianhua; Liu, Liren; Wu, Yu.

Afiliação

Yuan J; Beijing Hospital of Integrated Traditional Chinese and Western Medicine, Beijing, China.
Abdurahman A; Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Department of Molecular Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Cui N; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Hao T; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Zou J; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.
Liu L; Key Laboratory of Cancer Prevention and Therapy, National Clinical Research Center for Cancer, Tianjin's Clinical Research Center for Cancer, Department of Molecular Pharmacology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, China.
Wu Y; Xiyuan Hospital, China Academy of Chinese Medical Sciences, Beijing, China.

Front Pharmacol ; 14: 1091177, 2023.

Article em En | MEDLINE | ID: mdl-37324453

Palavras-chave

Huatan Sanjie Granules (HSG); PI3K-Akt/MAPK signaling pathways; adjuvant therapy; network pharmacology; primary liver carcinoma (PLC)

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Tipo de estudo: Etiology_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Idioma: En Revista: Front Pharmacol Ano de publicação: 2023 Tipo de documento: Article País de afiliação: China

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google